Drugs

Article	Citations
Prevention and Treatment of Monkeypox	356
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	257
BNT162b2 mRNA COVID-19 Vaccine: First Approval	253
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences	220
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	218
Inclisiran: First Approval	208
Lumasiran: First Approval	187
Nirmatrelvir Plus Ritonavir: First Approval	179
Acute Pancreatitis: Diagnosis and Treatment	176
Casimersen: First Approval	164
Aducanumab: First Approval	156
Sotorasib: First Approval	132
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile I	125
TRPV1-Targeted Drugs in Development for Human Pain Conditions	120
Setmelanotide: First Approval	111
Managing Diabetic Foot Ulcers: Pharmacotherapy for Wound Healing	110
Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update	110
Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects	102
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	101
Nivolumab Plus Relatlimab: First Approval	89
Orelabrutinib: First Approval	86
REGN-EB3: First Approval	85
Deucravacitinib: First Approval	84
Amivantamab: First Approval	82
Lonafarnib: First Approval	81

Remimazolam: A Review in Procedural Sedation	80
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder	78
Fabry Disease: The Current Treatment Landscape	78
Faricimab: First Approval	75
Belzutifan: First Approval	75
Abrocitinib: First Approval	71
Pralsetinib: First Approval	70
Disitamab Vedotin: First Approval	70
Savolitinib: First Approval	70
Vutrisiran: First Approval	69
Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain	67
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases	66
Tisotumab Vedotin: First Approval	65
Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations	64
Molnupiravir: First Approval	63
Cadonilimab: First Approval	63
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics	62
MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19	61
Telitacicept: First Approval	60
Casirivimab/Imdevimab: First Approval	60
Current Status of Clinical Trials on Tau Immunotherapies	60
Trilaciclib: First Approval	60
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	60
Efgartigimod: First Approval	59
Contezolid: First Approval	58
Loncastuximab Tesirine: First Approval	57
Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis	57
Infigratinib: First Approval	57
Tebentafusp: First Approval	57
Targeting AMPK by Statins: A Potential Therapeutic Approach	57
Lecanemab: First Approval	57
Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections	56
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update	55
Tirzepatide: First Approval	55
Envafolimab: First Approval	55
Ocrelizumab: A Review in Multiple Sclerosis	55
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals	54
Dostarlimab: First Approval	54
Pegcetacoplan: First Approval	53
Umbralisib: First Approval	52
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations	52
Filgotinib: First Approval	50
Tremelimumab: First Approval	50
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	50
Nirsevimab: First Approval	50
Naxitamab: First Approval	49
Donafenib: First Approval	49
Fuzuloparib: First Approval	47
Delandistrogene Moxeparvovec: First Approval	47
Odevixibat: First Approval	47

Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents	47
Anifrolumab: First Approval	47
Teclistamab: First Approval	46
Regdanvimab: First Approval	46
Therapeutic Options in Hereditary Optic Neuropathies	46
Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review	46
Givosiran: A Review in Acute Hepatic Porphyria	46
Mavacamten: First Approval	46
Mirvetuximab Soravtansine: First Approval	45
Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists	45
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review	45
Androgenetic Alopecia: Therapy Update	44
Lazertinib: First Approval	44
Adagrasib: First Approval	44
Spesolimab: First Approval	43
Tezepelumab: First Approval	43
Valoctocogene Roxaparvovec: First Approval	43
Etranacogene Dezaparvovec: First Approval	42
Voclosporin: First Approval	42
Sotrovimab: First Approval	41
Mosunetuzumab: First Approval	41
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes	41
Pamiparib: First Approval	40
Daridorexant: First Approval	40
Avacopan: First Approval	40
Melphalan Flufenamide (Melflufen): First Approval	39
Asciminib: First Approval	39
Finerenone: First Approval	39
Vericiguat: First Approval	39
Pacritinib: First Approval	38
Mobocertinib: First Approval	38
Pharmacotherapy for Amyotrophic Lateral Sclerosis: A Review of Approved and Upcoming Agents	38
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	38
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	37
Tixagevimab + Cilgavimab: First Approval	37
Lenacapavir: First Approval	37
REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	37
Evinacumab: First Approval	37
Ozoralizumab: First Approval	36
Olverembatinib: First Approval	36
Ibrexafungerp: First Approval	36
Futibatinib: First Approval	36
Margetuximab: First Approval	36
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy	36
Ansuvimab: First Approval	36
Tofersen: First Approval	36
Atogepant: First Approval	36
Are New Antiretroviral Treatments Increasing the Risk of Weight Gain?	35
Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	34
Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)	34
Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease	33
Maralixibat: First Approval	33
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa	33
Tapinarof Cream 1%: First Approval	32
Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies	31
Difelikefalin: First Approval	31
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	30
Belumosudil: First Approval	30
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	30
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?	30
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	30
The Potential Role of Clinical Metagenomics in Infectious Diseases: Therapeutic Perspectives	30
Omaveloxolone: First Approval	30
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC	30
Pimitespib: First Approval	30
Hetrombopag: First Approval	29
Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry	29
Oteseconazole: First Approval	29
Nemolizumab: First Approval	29
Ocular Toxicity of Targeted Anticancer Agents	28
Tralokinumab: First Approval	28
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	28
Ganaxolone: First Approval	28
Ritlecitinib: First Approval	27
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	27
The Effects of Osteoporotic and Non-osteoporotic Medications on Fracture Risk and Bone Mineral Density	27
Secukinumab: A Review in Psoriatic Arthritis	27
Avatrombopag: A Review in Thrombocytopenia	26
Enarodustat: First Approval	26
Dose Tapering of Biologics in Patients with Psoriasis: A Scoping Review	26

Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review	26
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	26
Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis	26
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	26
The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation	25
Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia	25
Evolving Strategies in the Treatment of Anaemia in Chronic Kidney Disease: The HIF-Prolyl Hydroxylase Inhibitors	25
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	25
Furmonertinib: First Approval	24
Nadofaragene Firadenovec: First Approval	24
Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals	24
Maribavir: First Approval	24
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease	24
Contemporary Management of Dyslipidemia	24
Estetrol/Drospirenone: A Review in Oral Contraception	23
Vosoritide: First Approval	23
Ponesimod: First Approval	23
New Topical Therapies in Development for Atopic Dermatitis	23
Serplulimab: First Approval	23
Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting	23
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	23
Elacestrant: First Approval	22
Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?	22
Ozanimod: A Review in Ulcerative Colitis	22
Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity	22
Baricitinib for the Treatment of Alopecia Areata	22
Emerging Options for the Prevention and Management of Clostridioides difficile Infection	22
Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020	21
Bupivacaine/Meloxicam Prolonged Release: A Review in Postoperative Pain	21
Nedosiran: First Approval	21
Retifanlimab: First Approval	21
Personalized Multimorbidity Management for Patients with Type 2 Diabetes Using Reinforcement Learning of Electronic Health Records	21
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease	21
Tirbanibulin: First Approval	21
Pathophysiology and Management of Variceal Bleeding	21
Olipudase Alfa: First Approval	21
Avacincaptad Pegol: First Approval	21
Gefapixant: First Approval	21
Rezafungin: First Approval	21
Drug Treatment of Cluster Headache	21
Current Medical Therapy for Adenomyosis: From Bench to Bedside	21
Budesonide/Glycopyrronium/Formoterol: A Review in COPD	20
Pirtobrutinib: First Approval	20
Bimekizumab for the Treatment of Psoriasis	20
Pharmacologic Management of Persistent Pain in Cancer Survivors	20
Avalglucosidase alfa: First Approval	20
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer	20
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	20
Glofitamab: First Approval	20
New Drug Delivery Systems Developed for Brain Targeting	19
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer	19
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome	19
Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease	19
Sparsentan: First Approval	19
Cancer Pain Treatment Strategies in Patients with Cancer	19
Olanzapine/Samidorphan: First Approval	19
Valemetostat Tosilate: First Approval	19
Surufatinib: First Approval	19
Clinical Value of Emerging Bioanalytical Methods for Drug Measurements: A Scoping Review of Their Applicability for Medication Adherence and Therapeutic Drug Monitoring	18
Amubarvimab/Romlusevimab: First Approval	18
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	18
Penpulimab: First Approval	18
Improving Treatment Options for Primary Hyperoxaluria	18
Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review	18
Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	18
Fostamatinib: A Review in Chronic Immune Thrombocytopenia	18
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria	18
Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain	17
Sugemalimab: First Approval	17
Chiglitazar: First Approval	17
Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer	17
Berotralstat: First Approval	17
Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases	17
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	16
Targeting the Angiopoietin/Tie Pathway: Prospects for Treatment of Retinal and Respiratory Disorders	16
Talquetamab: First Approval	15
Clazosentan: First Approval	15
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care	15
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	15
Fezolinetant: First Approval	15
Recent Advances in Antiarrhythmic Drug Therapy	15
Resmetirom: First Approval	15
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	15
From a Symptom-Based to a Mechanism-Based Pharmacotherapeutic Treatment in Complex Regional Pain Syndrome	15
Imeglimin: Current Development and Future Potential in Type 2 Diabetes	15
Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis	15
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease	15
Zavegepant: First Approval	15
Imeglimin Hydrochloride: First Approval	14
IL-31 Inhibition as a Therapeutic Approach for the Management of Chronic Pruritic Dermatoses	14
Treatment Sequencing for Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer	14
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease	14
Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology	14
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis	14
Dasiglucagon: First Approval	14